Fritextsökning
Artiklar per år
Innehållstyper
-
Svensk ettåring gör internationell affär
Xbrane Bioscience har ingått ett licensavtal med ett USA-baserat bioteknikföretag.
-
Mer pengar till europeisk forskning
Lund-deklarationen, som blev resultatet av förra veckans forskningskonferens i Lund, stämmer väl med regeringens prioriteringar, enligt högskole- och forskningsministern Tobias Krantz.
-
Vinnova ger miljoner till svensk-indiska projekt
Tillsammans med indiska Department of Biotechnology kommer Vinnova att satsa pengar på tuberkulosforskning. Vinnova räknar med att bidra med 16 miljoner till den svenska delen av projekten.
-
With their hands on the legal levers
It is wonderful news for the Scandinavian scientific community. At the end of May it stood clear that Lund will host to the European Spallation Source.
-
The winner of the race
She learned how to work hard at an early age and her devotion has certainly paid off. Whether it is field running or running a company, the key to success is focus according to Yvonne Mårtensson.
-
Sverige populärast på BIO2009
Rekordmånga besökare kom for att höra Jonas Frisén från Karolinska Institutet berätta om svensk stamcellsforskning.
-
Dags igen för världens största branschmöte
Den 18 maj slogs portarna upp for BIO2009 i Atlanta, Georgia. På agendan för de 15 000 besökarna stog bland annat Elton John och ett svenskt stamcellsseminarium.
-
Koldioxidinkubatorer baserade på innovativ teknologi
Galaxy är en ny förbättrad serie koldioxidinkubatorer från New Brunswick Scientific.
-
Ex-diplomat ska leda Navamedic
Han har tidigare varit svensk toppdiplomat i Indien. Nu tar han över rodret i det norska specialty pharmabolaget.
-
Astrazeneca i patentstrid
En generisk version av Pulmicort har godkänts för försäljning i USA. Patentintrång, hävdar Astrazeneca och stämmer nu bolaget bakom ansökan.
-
Astrachef blir hedersdoktor
En av de tre nya hedersdoktorerna vid KI är en av Sveriges tyngsta näringslivsprofiler.
-
Major changes to the Q-Med board
The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.
-
Faster sales but less profits for Probi
The probiotic company increases its turnover, and the net results are twice as large as last year.
-
Swedish top scientists to EMBO
Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and one is from the University of Uppsala.
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.
-
First ever study of human stem cell treatment
The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.
-
Athera signs production partnership
The companys novel cardiovascular product will be manufactured in Germany.
-
Re-painting the big pig-ture
Why do tame pigs show such variety in colouring, when their wild relatives are so plain? Swedish researchers know who is to blame. But the big question is why.
-
Go ahead for leg wound study
Tripep starts a phase II-study of their wound healing joint venture project.
-
Teams up with leading dermatologist
Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.
-
Test if you carry the fat virus
In a soon future there may be a quick and simple test that could show if you are infected with Ad-36, a human adenovirus that can make you over-weight.
-
New study of toxins and heart disease
Is there a correlation between exposure to hormone interfering environmental toxins and increased risk of developing cardiovascular disease? A new patient study will try to evaluate this, and one thousand people are to be included.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
Lundbeck divests companies
The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.
BREAKING